NCT01581073View on ClinicalTrials.gov

PRevention of End Stage Kidney Disease by Darbepoetin Alfa In Chronic Kidney Disease Patients With nondiabeTic Kidney Disease

PHASE3CompletedINTERVENTIONAL
Enrollment

476

Participants

Timeline

Start Date

February 16, 2012

Primary Completion Date

December 7, 2017

Study Completion Date

December 7, 2017

Conditions
Chronic Kidney DiseaseDiabetes
Interventions
DRUG

Darbepoetin alfa

Darbepoetin alfa is used for targeting Hb level of 11-13g/dL in high Hb group, and 9-11g/dL in low Hb group.

Trial Locations (1)

Unknown

Showa University School of Medicine, Shinagawa

All Listed Sponsors
collaborator

Showa University School of Medicine

UNKNOWN

lead

Translational Research Center for Medical Innovation, Kobe, Hyogo, Japan

OTHER

NCT01581073 - PRevention of End Stage Kidney Disease by Darbepoetin Alfa In Chronic Kidney Disease Patients With nondiabeTic Kidney Disease | Biotech Hunter | Biotech Hunter